Screener
Kyverna Therapeutics, Inc. KYTX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ equity | ||
| Preferred stock, 10,000,000 shares authorized, $0.00001 par value, no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.00001 par value; 490,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 60,532,500 and 60,389,893 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | 1 | 1 |
| Additional paid-in capital | 660,230 | 657,005 |
| Accumulated other comprehensive income/(loss) | (96) | 97 |
| Accumulated deficit | (464,555) | (424,827) |
| Total stockholders’ equity | 195,580 | 232,276 |
| Total liabilities and stockholders’ equity | $257,024 | $293,826 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s retained earnings?
- Kyverna Therapeutics, Inc. (KYTX) reported retained earnings of -$464.56M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s retained earnings changed year-over-year?
- Kyverna Therapeutics, Inc.'s retained earnings decreased by 50.8% year-over-year, from -$308.16M to -$464.56M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s retained earnings?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s retained earnings has grown at a 76.7% compound annual growth rate (CAGR), from -$136.04M to -$424.83M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Kyverna Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude